MSD in India has announced leadership change. K. G.
Ananthakrishnan (KG) current Managing Director of MSD in India will retire in
the beginning of 2017 and Vivek Vasudev Kamath will assume role of Managing
Director Designate from December 16, 2016. MSD in India operates its
business in India through three legal entities, MSD Pharmaceuticals Private
Limited, Organon (India) Private Limited, and Fulford (India) Limited.
Vivek joined MSD in India in July 2012 and is currently the
Business Unit Director for Cardiovascular Metabolics and Market Access. KG and
Vivek will work together to ensure smooth transition of business
responsibilities.
Announcing the leadership change, Jan Van Acker, President Asia
Pacific Region, MSD said, “I thank KG for his leadership and his contributions
to MSD over the past ten years and congratulate Vivek on assuming the role of
Managing Director of MSD in India. MSD has a robust succession planning process
through which Vivek was identified to lead MSD in India and to deliver on our
commitment to patients and communities in the Country. He has successfully led
our Cardiovascular Metabolics and Market Access businesses and has fostered
collaborative relationships with our customers and business partners, while
delivering strong growth”
Vivek Vasudev Kamath has over twenty five years of experience
across India, South Asia and ASEAN markets. He brings rich experience with
leading Indian and Multinational healthcare organizations in marketing, sales
and general management. He has managed portfolios in prescription, over-the
counter (OTC) and Diagnostics segments, partnering with healthcare
professionals, consumers, diverse trade channels and Government/ non-Government
healthcare entities.
No comments:
Post a Comment